A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALAN-PREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA: EFFECT OF AGE AND CO-MORBIDITIES

被引：0
|
作者：
Palumbo, A. [1 ]
Bringhen, S. [1 ]
Rossi, D. [2 ]
Cavalli, M. [2 ]
Ria, R. [2 ]
Offidani, M. [2 ]
Nozzoli, C. [2 ]
Baldini, L. [2 ]
De Rosa, L. [2 ]
De Sabbata, G. [2 ]
Liberati, A. M. [2 ]
Crippa, C. [2 ]
Ciambelli, F. [2 ]
Callea, V. [2 ]
Spriano, M. [2 ]
Ferrara, F. [2 ]
Elice, F. [2 ]
Galli, M. [2 ]
Peccatori, J. [2 ]
Catalano, L. [2 ]
Rizzo, M. [2 ]
Marasca, R. [2 ]
Pisani, F. [2 ]
Cavo, M. [2 ]
Petrucci, M. [2 ]
Musto, P. [2 ]
Omede, P. [1 ]
Larocca, A. [1 ]
Gaidano, G. [2 ]
Boccadoro, M. [1 ]
机构：
[1] AOU San Giovanni Battista, Turin, Italy
[2] Italian Multiple Myeloma Network, Gimema, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0568
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [31] Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)
    Hyeon-Seok Eom
    Yeo-Kyeoung Kim
    Joo-Seop Chung
    Kihyun Kim
    Hyo Jung Kim
    Ho Young Kim
    Jong-Youl Jin
    Young-Rok Do
    Suk-Joong Oh
    Cheolwon Suh
    Chu-Myong Seong
    Chul Soo Kim
    Dong Soon Lee
    Jae Hoon Lee
    [J]. Annals of Hematology, 2010, 89 : 489 - 497
  • [32] Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)
    Eom, Hyeon-Seok
    Kim, Yeo-Kyeoung
    Chung, Joo-Seop
    Kim, Kihyun
    Kim, Hyo Jung
    Kim, Ho Young
    Jin, Jong-Youl
    Do, Young-Rok
    Oh, Suk-Joong
    Suh, Cheolwon
    Seong, Chu-Myong
    Kim, Chul Soo
    Lee, Dong Soon
    Lee, Jae Hoon
    [J]. ANNALS OF HEMATOLOGY, 2010, 89 (05) : 489 - 497
  • [33] VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients.
    Colado, Enrique
    Mateos, Maria-Victoria
    Moreno, Maria-Jose
    Dearriba, Felipe
    de la Rubia, Javier
    Lahuerta, Juan Jose
    Iniesta, Pastora
    Viguria, Maria Cruz
    Gonzalez, Ana Pilar
    Garcia-Sanz, Ramon
    Olazabal, Juan
    Miguel, Jesus F. San
    [J]. BLOOD, 2008, 112 (11) : 1265 - 1266
  • [34] A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
    Sacchi, Stefano
    Marcheselli, Raffaella
    Lazzaro, Antonio
    Morabito, Fortunato
    Fragasso, Alberto
    Di Renzo, Nicola
    Balleari, Enrico
    Neri, Santo
    Quarta, Giovanni
    Ferrara, Raimondo
    Vigliotti, Maria Luigia
    Polimeno, Giuseppe
    Musto, Pellegrino
    Consoli, Ugo
    Zoboli, Alessandra
    Buda, Gabriele
    Pastorini, Alessandro
    Masini, Luciano
    [J]. LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1942 - 1948
  • [35] Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy.
    Wang, M
    Delasalle, K
    Giralt, S
    Alexanian, R
    [J]. BLOOD, 2005, 106 (11) : 231A - 231A
  • [36] Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients
    Christopher Strouse
    Sarah L. Mott
    Brian J. Smith
    Margarida Magalhaes-Silverman
    Umar Farooq
    Fenghuang Zhan
    Yogesh Jethava
    Guido Tricot
    [J]. Bone Marrow Transplantation, 2024, 59 : 128 - 130
  • [37] Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients
    Strouse, Christopher
    Mott, Sarah L.
    Smith, Brian J.
    Magalhaes-Silverman, Margarida
    Farooq, Umar
    Zhan, Fenghuang
    Jethava, Yogesh
    Tricot, Guido
    [J]. BONE MARROW TRANSPLANTATION, 2024, 59 (01) : 128 - 130
  • [38] Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group.
    Beksac, Meral
    Haznedar, Rauf
    Firatli-Tuglular, Tulin
    Ozdogu, Hakan
    Aydogdu, Ismet
    Konuk, Nahide
    Sucak, Gulsan
    Kaygusuz, Isik
    Karakus, Sema
    Kaya, Emin
    Ali, Ridvan
    Gulbas, Zafer
    Ozet, Gulsum
    Goker, Hakan
    Undar, Levent
    [J]. BLOOD, 2009, 114 (22) : 746 - 747
  • [39] Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial
    Verelst, S.
    Termorshuizen, F.
    Uyl-de Groot, C.
    Schaafsma, M. R.
    Ammerlaan, R.
    Wittebol, S.
    Sinnige, H.
    Zweegman, S.
    Kooy, M. van Marwijk
    van der Griend, R.
    Lokhorst, H.
    Sonneveld, P.
    Wijermans, P.
    [J]. BLOOD, 2010, 116 (21) : 1225 - 1226
  • [40] Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
    Verelst, Silvia G. R.
    Termorshuizen, F.
    Uyl-de Groot, C. A.
    Schaafsma, M. R.
    Ammerlaan, A. H. M.
    Wittebol, S.
    Sinnige, H. A. M.
    Zweegman, S.
    Kooy, M. van Marwijk
    van der Griend, R.
    Lokhorst, H. M.
    Sonneveld, P.
    Wijermans, P. W.
    [J]. ANNALS OF HEMATOLOGY, 2011, 90 (12) : 1427 - 1439
12345